Arecoline Fundamentals Explained
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge multiple intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Main trial goals have been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suff